Drug intelligence / Profile preview

Accell Plus

Development stage
Unknown
Lead developer
Integra LifeSciences
Administration
Topical
01

Overview

Accell Plus is a demineralized bone matrix (DBM) putty developed by Integra LifeSciences for use as a bone graft substitute in orthopedic and spinal surgeries. It is composed of a combination of demineralized bone matrix and the proprietary Accell Bone Matrix (ABM), which is a more soluble and dispersed form of DBM. This formulation is designed to maximize the surface area of the bone-derived growth factors, particularly bone morphogenetic proteins (BMPs), thereby enhancing the product's osteoinductive potential. Accell Plus provides an osteoconductive scaffold that supports the attachment and proliferation of osteogenic cells while simultaneously inducing the differentiation of mesenchymal stem cells into bone-forming osteoblasts. It is primarily indicated for filling bone voids or gaps that are not intrinsic to the stability of the bony structure.

Brand names
Accell Plus
Other names
Accell Plus DBMAccell Plus Bone Graft Substitute
02

Targets

BMPR (Bone morphogenetic protein receptor)

Beyond the preview

Go deeper on Accell Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accell Plus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call